Low unesterified:esterified eicosapentaenoic acid (EPA) plasma concentration ratio is associated with bipolar disorder episodes, and omega‐3 plasma concentrations are altered by treatment

Abstract

Objectives Omega (n)-3 and n-6 polyunsaturated fatty acids (PUFA) are molecular modulators of neurotransmission and inflammation. We hypothesized that plasma concentrations of n-3 PUFA would be lower and of n-6 PUFA higher in subjects with bipolar disorder (BD) compared to healthy controls (HC), and would correlate with symptom severity in subjects with BD, and that effective treatment would correlate with increased n-3 but lower n-6 PUFA levels. Additionally, we explored clinical correlations and group differences in plasma levels of saturated and monounsaturated fatty acids. Methods This observational, parallel group study compared biomarkers between HC (n = 31), and symptomatic subjects with BD (n = 27) when ill and after symptomatic recovery (follow-up). Plasma concentrations of five PUFA [linoleic acid (LA), arachidonic acid (AA), alpha-linolenic acid (ALA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA)], of two saturated fatty acids (palmitic acid and stearic acid) and of two monounsaturated fatty acids (palmitoleic acid, oleic acid) were measured in esterified (E) and unesterified (UE) forms. Calculated ratios included UE:E for the five PUFA, ratios of n-3 PUFA (DHA:ALA, EPA:ALA, EPA:DHA), and the ratio of n-6:n-3 AA:EPA. Comparisons of plasma fatty acid levels and ratios between BD and HC groups were made with Student t-tests, between the BD group at baseline and follow-up using paired t-tests. Comparison of categorical variables was performed using Chi-square tests. Pearson’s r was used for bivariate correlations with clinical variables, including depressive and manic symptoms, current panic attacks, and psychosis. Results UE EPA was lower in BD than HC, with a large effect size (Cohen’s d = 0.86, p < 0.002), however, it was not statistically significant after correction for multiple comparisons. No statistically significant difference was seen in any plasma PUFA concentration between BD and HC after Bonferroni correction for 40 comparisons, at p < 0.001. Neither depressive severity nor mania severity was correlated significantly with any PUFA concentration. Exploratory comparison showed lower UE:E EPA in BD than HC (p < 0.0001). At follow-up in the BD group, UE, E DHA:ALA, and UE EPA:ALA were decreased (p < 0.002). Exploratory correlations of clinical variables revealed that mania severity and suicidality were positively correlated with UE:E EPA ratio, and that several plasma levels and ratios correlated with panic disorder and psychosis. Depressive severity was not correlated with any ratio. No plasma fatty acid level or ratio correlated with self-reported n-3 PUFA intake or use of medication by class. Conclusions A large effect size of reduced UE EPA, and a lower plasma UE:E concentration ratio of EPA in the symptomatic BD state may be an important factor in vulnerability to a mood state. Altered n-3 PUFA ratios could indicate changes in PUFA metabolism concurrent with symptom improvement. Our findings are consistent with preclinical and postmortem data and suggest testing interv...

Plasma metabolic profile delineates roles for neurodegeneration, pro-inflammatory damage and mitochondrial dysfunction in the FMR1 premutation

“…From the variety of medications that both groups were receiving (see Methods), carriers were more likely to be taking antidepressants than controls (30.4% vs. 6.25%; p < 0.0001); among them, the most common class was the selective serotonin reuptake inhibitors (SSRI; n = 6, including one control). However, no difference in metabolite levels was observed in our study consistent with the lack of differences in PUFA levels between medicated and unmedicated subjects reported by others [56,57], No unmedicated subjects were present in any group, but we did not find that the metabolomics data correlated with the presence of the iatrogenic compounds indicated above or with antidepressants, antipsychotics, or mood stabilizers.…”

Meta‐analysis of erythrocyte polyunsaturated fatty acid biostatus in bipolar disorder

“…Moreover, similar erythrocyte DHA deficits were observed in studies employing adolescent or adult patients, and studies employing medicated or unmedicated patients. Although plasma fatty acid levels are more variable, it is also worth noting that a prior caseÀcontrol study (28), but not others (6,29,30), similarly observed DHA deficits in plasma from patients with bipolar disorder. The present results suggest that bipolar I disorder is associated with robust and selective erythrocyte DHA deficits, and add to a growing body of evidence implicating omega-3 PUFA deficiency in the pathophysiology of bipolar I disorder.…”

Total sleep time and kynurenine metabolism associated with mood symptom severity in bipolar disorder

“…Additional measures were collected but not used for this analysis. For more detailed report on methods and results of analysis of fatty acid concentrations, please see Saunders, et al 35…”